Study of Medtronic, Inc. Endeavor® Drug-Eluting Stent Demonstrates Long-Term Advantages over Taxus® DES

SAN FRANCISCO--(BUSINESS WIRE)--New research findings released at TCT 2011 show that the Endeavor® zotarolimus-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) outperformed Boston Scientific Corp.’s Taxus® paclitaxel-eluting stent on standard measures of safety and efficacy through five years of clinical follow-up.